Return On Capital Employed Overview: Neos Therapeutics
During Q2, Neos Therapeutics (NASDAQ: NEOS) brought in sales totaling $13.13 million. However, earnings decreased 51.17%, resulting in a loss of $2.88 million. In Q1, Neos Therapeutics brought in $14.49 million in sales but lost $5.89 million in earnings.
Why ROCE Is Significant
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Neos Therapeutics posted an ROCE of 0.18%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Neos Therapeutics, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.
Q2 Earnings Insight
Neos Therapeutics reported Q2 earnings per share at $-0.11/share, which beat analyst predictions of $-0.13/share.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
